TY - JOUR
T1 - Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors
T2 - A Report from the Blood or Marrow Transplant Survivor Study
AU - Gangaraju, Radhika
AU - Chen, Yanjun
AU - Hageman, Lindsey
AU - Wu, Jessica
AU - Francisco, Liton
AU - Battles, Kevin
AU - Kung, Michelle
AU - Ness, Emily
AU - Parman, Mariel
AU - Weisdorf, Daniel J.
AU - Forman, Stephen J.
AU - Arora, Mukta
AU - Armenian, Saro H.
AU - Bhatia, Smita
N1 - Funding Information:
Financial disclosure : This study was supported in part by grants from the National Cancer Institute (R01 CA078938 and U01 CA213140) and the Leukemia and Lymphoma Society (R6502-16) (to S.B.).
Publisher Copyright:
© 2019 American Society for Transplantation and Cellular Therapy
PY - 2019/11
Y1 - 2019/11
N2 - Hemostatic complications are commonly encountered in blood or marrow transplantation (BMT) recipients, increasing their morbidity and mortality and are well described in the immediate post-transplantation period. The risk of venous thromboembolism (VTE) in long-term survivors of autologous BMT has not been studied previously. Patients who underwent autologous BMT between January 1, 1974, and December 31, 2010 for a hematologic malignancy, lived 2 years or more after transplantation, and were age ≥18 years were surveyed for long-term outcomes. The median duration of follow-up was 9.8 years (interquartile range, 6.4 to 14.3 years). We analyzed the risk of VTE in 820 autologous BMT recipients who survived for ≥2 years, compared with 644 siblings. BMT survivors were at a 2.6-fold higher risk of VTE compared with siblings (95% confidence interval [CI], 1.6 to 4.4; P =.0004), after adjusting for sociodemographic characteristics. Conditional on surviving for ≥2 years after BMT, the mean cumulative incidence of VTE was 3.9 ± .8% at 5 years and 6.1 ± 1.1% at 10 years. A diagnosis of plasma cell disorder (hazard ratio [HR], 2.37; 95% CI, 1.3 to 4.2; P = .004) and annual household income ≤$50,000 (HR, 2.02; 95% CI, 1.2 to 3.6; P = .015) were associated with increased VTE risk. Our data indicate that autologous BMT survivors are at elevated risk for developing late-occurring VTE. The development of risk prediction models to identify autologous BMT survivors at greatest risk for VTE and thromboprophylaxis may help decrease the morbidity and mortality associated with VTE.
AB - Hemostatic complications are commonly encountered in blood or marrow transplantation (BMT) recipients, increasing their morbidity and mortality and are well described in the immediate post-transplantation period. The risk of venous thromboembolism (VTE) in long-term survivors of autologous BMT has not been studied previously. Patients who underwent autologous BMT between January 1, 1974, and December 31, 2010 for a hematologic malignancy, lived 2 years or more after transplantation, and were age ≥18 years were surveyed for long-term outcomes. The median duration of follow-up was 9.8 years (interquartile range, 6.4 to 14.3 years). We analyzed the risk of VTE in 820 autologous BMT recipients who survived for ≥2 years, compared with 644 siblings. BMT survivors were at a 2.6-fold higher risk of VTE compared with siblings (95% confidence interval [CI], 1.6 to 4.4; P =.0004), after adjusting for sociodemographic characteristics. Conditional on surviving for ≥2 years after BMT, the mean cumulative incidence of VTE was 3.9 ± .8% at 5 years and 6.1 ± 1.1% at 10 years. A diagnosis of plasma cell disorder (hazard ratio [HR], 2.37; 95% CI, 1.3 to 4.2; P = .004) and annual household income ≤$50,000 (HR, 2.02; 95% CI, 1.2 to 3.6; P = .015) were associated with increased VTE risk. Our data indicate that autologous BMT survivors are at elevated risk for developing late-occurring VTE. The development of risk prediction models to identify autologous BMT survivors at greatest risk for VTE and thromboprophylaxis may help decrease the morbidity and mortality associated with VTE.
KW - Autologous BMT
KW - BMT survivors
KW - Plasma cell dyscrasia
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85069842509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069842509&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2019.06.032
DO - 10.1016/j.bbmt.2019.06.032
M3 - Article
C2 - 31278995
AN - SCOPUS:85069842509
SN - 1083-8791
VL - 25
SP - 2261
EP - 2266
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 11
ER -